Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags

2026-03-12 15:39:54 ET

Investment Overview

Armata Pharmaceuticals, Inc. ( ARMP ) stock began trading on the New York Stock Exchange in May 2019 as a result of a merger between C3J Therapeutics and AmpliPhi Biosciences Corporation. At the time, Armata discussed its business as follows:

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology.

Armata's lead product candidate, AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. The Company is also developing and advancing a broad pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa , leveraging its proprietary phage-specific GMP manufacturing capabilities.

Read the full article on Seeking Alpha

For further details see: